![](https://endpts.com/wp-content/uploads/2021/08/Raul-Rodriguez-Rigel-tile-scaled.jpg)
Raul Rodriguez, Rigel CEO
Covid-19 roundup: Tiny sample size leads FDA to turn down Rigel's EUA; Seattle biotech to co-develop mRNA vaccine in South Korea
Four months after Rigel announced possible Phase II results for its Covid-19 treatment, the FDA has deemed the sample size too …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.